Vimarsana
Biggest News Aggregation in the World

Recommended Supplementation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Recommended Supplementation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Recommended Supplementation Today - Breaking & Trending Today

Ionis Publishes 2023 Corporate Responsibility Report - Vimarsana News

Ionis Publishes 2023 Corporate Responsibility Report

Established new corporate responsibility strategic pillars and actionable goals Received approval for two Ionis-discovered medicines in 2023, and continued to advance a broad pipeline poised to...

Ionis reports fourth quarter and full year 2023 financial results - Vimarsana News

Ionis reports fourth quarter and full year 2023 financial results

WAINUA™ approved with launch underway; on track for EU and Canada approval decisions this year Positive Phase 3 olezarsen and donidalorsen data, preparing regulatory submissions for FCS and HAE,...

Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy - Vimarsana News

Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy

CARLSBAD, Calif., Feb. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to Ionis and AstraZeneca's...

Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases - Vimarsana News

Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases

– Numerous value-driving commercial, regulatory and pipeline milestones anticipated – CARLSBAD, Calif., Jan. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. today announced highlights from...

WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis - Vimarsana News

WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved Ionis and...